We believe we are uniquely positioned to help solve a huge medical unmet need in patients fighting a highly aggressive and lethal disease. With the current lack of effective therapies, ALS patients have an average life expectancy of 3-5 years. Unfortunately ALS is not as rare as commonly thought. The life time chance of getting ALS is actually 1 in 400 but because ALS is so rapidly fatal it seems more rare that it really is.
We have the ambition to contribute to advancing technologies and innovation that provide solutions for other diseases too. All the companies we are investing in develop drugs or technologies for multiple diseases, often using state of the art and groundbreaking new approaches such as gene therapy, precision medicine, and AI solutions. Therefore, our portfolio has the potential to impact society well beyond ALS. We use specific metric to track the impact of our investments.